Investigational drug · Phase 2
SGB-9768
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SGB-9768"
First trial start
2025
Jun 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SGB-9768", any sponsor or status.
Conditions studied
As listed on its trial records.
- PNH - Paroxysmal Nocturnal Hemoglobinuria
- IgA Nephropathy (IgAN)
- C3 Glomerulopathy
- IC-MPGN
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SGB-9768" as an intervention, largest first.
- A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruiting
Suzhou Sanegene Bio Inc.Industry
NCT06786338 · 45 participants · Start Jun 6, 2025 · Primary completion Dec 29, 2026
Drug: SGB-9768 · For: IgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGN
Sites: Beijing, China; Changsha, China; Chengdu, China · 11 sites in all
Suzhou Sanegene Bio Inc.Industry
NCT06501573 · 45 participants · Start Jul 18, 2024 · Primary completion May 7, 2026
Drug: SGB-9768 · For: Healthy Volunteer
Sites: Shanghai, China
- Study of SGB-9768 in Patients With Paroxysmal Nocturnal HemoglobinuriaNot yet recruiting
Suzhou Sanegene Bio Inc.Industry
NCT07796256 · 24 participants (planned) · Start Oct 31, 2026 · Primary completion Aug 31, 2027
Drug: SGB-9768 · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for PNH - Paroxysmal Nocturnal Hemoglobinuria
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.